CA3063938A1 — Compounds, compositions and methods
Assigned to Denali Therapeutics Inc · Expires 2018-11-22 · 7y expired
What this patent protects
The present disclosure relates generally to compounds of Formula I: pharmaceutically acceptable salts, deuterated analogs, stereoisomers, mixtures of stereoisomers, and tautomers thereof, and methods and compositions for preventing or arresting cell death and/or inflammation.
USPTO Abstract
The present disclosure relates generally to compounds of Formula I: pharmaceutically acceptable salts, deuterated analogs, stereoisomers, mixtures of stereoisomers, and tautomers thereof, and methods and compositions for preventing or arresting cell death and/or inflammation.
Drugs covered by this patent
- Crenessity (CRINECERFONT) · Neurocrine
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.